Market Place
Sourcing Support
HanchorBio Receives FDA Orphan Drug for HCB101 in Gastric Cancer
13 Feb 2026 //
PR NEWSWIRE
Hanchorbio, Wuxi Biologics Partner To Advance Fusion Protein
26 Jan 2026 //
PR NEWSWIRE BIO
Hanchorbio Presents HCB101 Orally At ESMO Immuno-Oncology
11 Dec 2025 //
PR NEWSWIRE
HanchorBio Shows Late-Breaking HCB101 Data At SITC 2025
07 Nov 2025 //
PR NEWSWIRE
Hanchorbio Presents Preclinical Data On HCB301 at SITC 2025
05 Nov 2025 //
PR NEWSWIRE
Hanchorbio Unveils HCB101 Phase 1 Clinical Results At FACO 2025
24 Oct 2025 //
PR NEWSWIRE
Hanchorbio`s HCB101 Cd47-Sirp? Therapy Accepted For Publication
23 Oct 2025 //
PR NEWSWIRE
Hanchorbio Secures US Patent For Sirp?/Cd47 Fusion Protein HCB101
21 Oct 2025 //
PR NEWSWIRE
HanchorBio Shares HCB101 & HCB301 Data at 5 Oncology Meetings
20 Oct 2025 //
PR NEWSWIRE
Hanchorbio To Present HCB301 Abstract At SITC 2025 Meeting
03 Oct 2025 //
PR NEWSWIRE
HanchorBio Advances Global Impact of HCB101 Immunotherapy
16 Jul 2025 //
PR NEWSWIRE
Henlius pens $202M pact for HanchorBio`s midstage CD47 blocker
02 Jul 2025 //
PR NEWSWIRE
HanchorBio, Henlius Ink Deal to Boost Immuno-Oncology with HCB101
01 Jul 2025 //
PR NEWSWIRE
HanchorBio Presents Data on HCB101 Checkpoint Inhibitor at ASCO
17 Jun 2025 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.